come nice like expect given
result line slightli better expect organ
revenu growth consist guidanc model
outlook reiter take closer look number howev
result particularli devic side bit mix diabet
heart failur perform exceed continu stellar area
misstep neuromod result management
acknowledg area vulner continu address
place could consid commerci inadequaci timelin
unchang item like libr mitraclip updat reimburs
sens investor hope management might say either could
go faster see chang expect bit today share slide
may hope surpris weak healthcar tape may
play part overal see littl risk abt stori
organ revenue assumpt may prove conserv new product
mitraclip function mr libr alin roll-out gain traction
think increas management focu lag area could lead better
futur result see continu strong growth
littl risk near term share trade ntm ep feel mani
posit price base valuat maintain neutral rate
posit data point libr diabet continu grow robust
rate quarter driven libr grew
quarter sale libr alarm submit
fda icgm current review agenc
continu expect product soon though timelin
provid appear anticip uptick libr
adopt emphas expand manufactur capac
product avail libr part
pipelin think rapid uptak cgm continu benefit
player least next coupl quarter expect dexcom
neutral beat street number mention preview
valuat maintain neutral rate risk page
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
report revenu slightli street-high forecast
neg impact currenc similar model
devic segment revenu consist expect ou
electrophysiolog diabet heart failur neutral shortfal within
neuromod structur heart note sequenti trend
structur healthi may over-model impact
mitraclip mitraclip limit detail provid compani
continu wait reimburs mitraclip function mitral
regurgit notabl compani remain enthusiast prospect
mitraclip mani market like japan count implant center
world-wide diabet revenu solid organ growth
libr sale sequenti libr perform
continu bolster favor payor trend strong demand
back impress real-world data
turn diagnost organ sale growth alin growth
continu stellar europ molecular diagnost weak
quarter declin organ due volatil purchas pattern
africa dont see long-term neg previous indic
pend fda approv compani hope roll broader test menu
 alin platform acceler growth back
report basi establish pharma came lower estim
portion shortfal attribut less favor currenc impact
model manag remain bullish opportun brazil
russia china exclud impact currenc region continu
lastli nutrit sale growth better expect
perform broad-bas strong growth seen asia latin
america
gross margin forecast sg spend
wors model came better
estim despit higher tax rate model deliv penni
beat vs forecast
make tweak forecast revenu keep
devic estim fairli steadi though within segment tweak
diabet heart failur estim lower neuromod
structur heart forecast turn busi trim
establish pharma forecast rais nutrit estim make
littl chang margin estim
net-net increas full year adj ep estim
primarili reflect penni beat
actualsbtig estimate variancetot incom net bpssg spend bpsr spend bpsebit bpstax bpssourc btig estim compani filingsvari
abbott rate neutral abbott valuat increas
last two year sinc compani acquir st jude medic compani
benefit solid pipelin launch high-growth area
diabet diagnost remain posit base
busi see pathway toward drive high-singl digit revenu growth
although mitraclip still modest portion busi expect
signific ramp label expans said share trade
premium comp group histor averag feel share
rel valuat appropri reflect risk vs reward btig provid
price target neutral-r stock risk rate includ multipl
healthcar fall favor fda regulatori agenc product
exhibit comp tabl large-cap peer
 net ep gross bpsnmadj ebit bpsnm btig estim compani filingsnewold changecagrntm johnsonjnjnot fishertmobuy bdxnot scientificbsxbuy factset data btig estimatesintra-day price ex-amortcompanytickerr ptpricemarket cap
abbott incom statement sale ex oper interest incom incom tax expens net ep methodology/abt share net incom ep incl disc marginsgross expensescog oper expens ep btig estim compani report
abbott segment laboratori y/i laboratori y/i growth laboratori y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth diagnost y/i diagnost y/i growth diagnost y/i growth oper adj y/i y/i growth y/i growth oper adj btig estim
abbott segment devicesrhythm manag y/i manag y/i growth manag y/i growth y/i y/i growth y/i growth failur y/i failur y/i growth failur y/i growth y/i y/i growth y/i growth heart y/i heart y/i growth heart y/i growth y/i y/i growth y/i growth y/i y/i growth y/i growth devic y/i devic y/i growth devic y/i growth totaltot report segment us y/i report segment y/i report segment ww y/i btig estim compani adjust stj acquisit optic divestitur
btig cover compani mention report
appendix analyst certif import disclosur
